GLPwatch
Papers (10389)
Page 156 of 174, ranked by citation count.
- Therapeutic effect of liraglutide on type 2 diabetic patients with nonalcoholic fatty liver disease.
- Semaglutide and Risk of Adult-Onset Seizure: A Target Trial Emulation.
- Novo sets sights on obesity market with diabetes drug.
- Acute gastric dilation associated with the use of semaglutide, a GLP-1 analogue.
- Clinical Benefits of Treating Patients with Type 2 Diabetes Mellitus with iGlarLixi: A Patient-Level Simulation Study.
- Semaglutide Reduces CV Events in High-Risk Patients with Type 2 Diabetes Mellitus.
- Survodutide Once Weekly for the Treatment of Adults with Obesity.
- Pharmacologic Treatment of Metabolic Dysfunction-Associated Steatotic Liver Disease in the Context of Type 2 Diabetes.
- Effects of acute GLP-1 analogue infusion on the glycemic and neurohormonal responses to meal test in non- hypoglycemic subjects after gastric bypass.
- [Effect of semaglutide on serum metabolomics in obese patients with type 2 diabetes mellitus complicated with metabolic-associated fatty liver disease].
- Effect of glucagon-like peptide-1 receptor agonists on heart rate in non-diabetic individuals with overweight or obesity: a systematic review and pairwise and network meta-analysis of randomized controlled trials.
- Drug Combo Adds No Benefit in Patients with Type 2 Diabetes.
- Efficacy of Glucagon-Like Peptide-1 Receptor Agonists for Psychological Well-Being and Depressive Symptoms: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
- Non-Arteritic Ischaemic Optic Neuropathy Associated with Semaglutide Use.
- A Comprehensive Review on the Cardioprotective and Nephroprotective Effects of Semaglutide, and Its Therapeutic Efficacy and Mechanisms in Cardiorenal Syndrome.
- Insulin and Incretin Receptor Agonists Reciprocally Alter Their Blood-Brain Barrier Permeabilities.
- Tirzepatide and metformin effects on hunger and BMI in an adolescent with hyperphagia and severe obesity due to MC4R Deficiency: a case report.
- Cost-Effectiveness of Tirzepatide for the Management of Heart Failure With Preserved Ejection Fraction and Obesity.
- Current priorities in research on metabolic-associated fatty liver disease based on the results of EASL - 2024.
- Cardiovascular adverse event reporting profile of tirzepatide: a real-world pharmacovigilance analysis of heart failure, arrhythmias, and ischemic events.
- Semaglutide and Cardiovascular Outcomes.
- Lax oversight of semaglutide advertising could harm patients, warn critics.
- Semaglutide-Mediated Remodeling of Adipose Tissue in Type 2 Diabetes: Molecular Mechanisms Beyond Glycemic Control.
- Tirzepatide-induced Weight Loss in Overweight or Obese Midlife Adults with and without Type 2 Diabetes: A Real-world Comparative Cohort Study.
- Impact of Liraglutide 3.0 mg on Metabolic Dysfunction-Associated Steatotic Liver Disease in Individuals with Obesity: A Real-World Study.
- Hormone copycats.
- Reestimation of Medicare Spending for Semaglutide After Most Favored Nation and Medicare Drug Price Negotiation Announcements.
- Liraglutide alleviates sepsis-associated encephalopathy via attenuating neuronal damage, glial cell activation and mitochondrial dysfunction in a mouse model of sepsis.
- Once-Weekly Semaglutide in Adolescents with Obesity.
- Persistent Adipose Inflammation Despite Metabolic Recovery Reveals Tissue-Specific Immunomodulation by Tirzepatide.
- Association of semaglutide use with outcomes in chronic plantar heel pain: a prospective observational cohort and a pilot interventional study.
- Effect of Tirzepatide on the Risk of Developing Type 2 Diabetes Mellitus Among the People Living With Obesity or Overweight: A Systematic Review.
- [Comparison of therapeutic effect of metformin hydrochloride/vildagliptin and liraglutide on type 2 diabetes mellitus in obese patients].
- Semaglutide in patients with hidradenitis suppurativa and obesity.
- Optimization of patient and site engagement in the SYNCHRONIZE™ phase 3 clinical trial program for survodutide in obesity through clinical trial simulation.
- Reply.
- [Effect of byetta on renal osmoregulatory function in patients with diabetes mellitus].
- Hypoglycemics for the treatment of type 2 diabetes in patients with chronic kidney disease: a focus on new agents.
- Psychometric Validation of the Simplicity of Diabetes Treatment Questionnaire (Sim-Q) for Type 2 Diabetes.
- Exenatide attenuates neuroinflammation and rescues sepsis-induced depressive behavior and cognitive dysfunction in a mouse model.
- Efficacy comparison of dapagliflozin combined with liraglutide versus monotherapy in obese patients with heart failure.
- Amelioration of D-galactose-induced hyposalivation in aging rats by the GLP-1 receptor agonist Exendin-4.
- Assessment of cardiovascular event reduction with SGLT2 inhibitors compared to GLP-1 receptor agonists in type 2 diabetes mellitus.
- [Effect of semaglutide treatment on the body weight and the glucose, insulin and thyroid hormone levels in aging rats with diet-induced obesity.]
- In patients ≥ 50 years with type 2 diabetes and CV disease or risk factors, oral semaglutide did not increase CV events.
- Assessment of noninferiority of oral vs subcutaneous semaglutide: a systematic review and meta-analysis.
- Semaglutide may reduce cardiovascular disease and heart failure.
- European Society of Cardiology 2018.
- [Cardiac effects of glucagon-like peptide 1].
- Rational construction of porous cobalt nanoparticle integrated nitrogen doped hollow carbon nanostructures for peptide agonist exendin-4 biosensing.
- Anti-obesity compounds, Semaglutide and LiPR, and PrRP do not change the proportion of human and mouse POMC+ neurons.
- A qualitative study exploring experiences about using semaglutide for weight loss in a rural setting in Denmark - 'she is probably on the meds'.
- The Ethics of Wegovy in Pediatric Mental Health.
- Liraglutide in Prader Willi-Syndrome: The Importance of Placebo-Controlled Studies.
- Examination of quality of life in patients using exenatide with different dimensions.
- GLP1R and OCT1 variants modulate semaglutide and metformin response in type 2 diabetes.
- Therapeutic potential of liraglutide in rheumatoid arthritis: Modulation of inflammation, apoptosis, and metabolic dysfunction in a rat model.
- GLP-1 receptor agonist therapy before bariatric surgery: Effects on weight loss and body composition in clinical practice.
- Real-world use of semaglutide for obesity treatment: A cohort study in an integrated health care delivery system.
- Energy-Metabolism-Enhancing Probiotics Enhance the Therapeutic Response to a Glucagon-like Peptide-1 Receptor Agonist.